London, 15 September 2015: Technavio, the independent tech-focused global research firm, has published a report on the global solubility enhancement excipients market for OSDF 2015-2019, which is expected to grow at a CAGR of around 15.1% between 2015 and 2019.
The cost of solubility-enhancing excipients is expected to increase at a rapid rate, compared with the growth in production volume. An increasing number of OSDF drugs have low solubility, and hence the demand for solubility-enhancing excipients is increasing. Vendors of generic drugs are focusing on product differentiation by enhancing drug characteristics like solubility.
“Silica is expected to be the fastest-growing category of solubility-enhancing excipients in the others segment. Currently, numerous projects aiming to explore the potential of both bimodal and mesoporous silica in vitro and in vivo are underway,” says Faisal Ghaus, Vice President of Technavio.
“The use of mesoporous silica in enhancing the solubility of anti-inflammatory drugs such as aceclofenac and celecoxib is being studied.”
Key Market Drivers
- Development of poorly soluble drugs
- Introduction of super-generics
- Growing demand from APAC
- Vendor focus on smaller segments
Key Market Trends
- Introduction of silica-based products
- Emergence of custom manufacturers
- Increasing number of collaborations
- Growing focus on nanotechnology-based solubility-enhancing excipients
Key Market Vendors
- Abitec
- Ashland
- BASF
- Croda
- Dow
- Evonik
- Gattefosse
- Shin-Etsu
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
